LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.33 -8.26

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.29

Max

3.63

Chiffres clés

By Trading Economics

Revenu

1.9M

-68M

Ventes

-5.8M

42M

Marge bénéficiaire

-163.26

Employés

570

EBITDA

25M

-41M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+23.63% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

60M

1.1B

Ouverture précédente

11.59

Clôture précédente

3.33

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 nov. 2025, 18:59 UTC

Principaux Mouvements du Marché

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov. 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov. 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov. 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov. 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov. 2025, 22:06 UTC

Acquisitions, Fusions, Rachats

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov. 2025, 22:02 UTC

Résultats

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov. 2025, 22:02 UTC

Résultats

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov. 2025, 22:02 UTC

Résultats

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 nov. 2025, 21:40 UTC

Résultats

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov. 2025, 21:40 UTC

Résultats

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov. 2025, 21:39 UTC

Résultats

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov. 2025, 21:38 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 21:38 UTC

Résultats

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov. 2025, 21:10 UTC

Résultats

XP Inc. 3Q EPS BRL2.47 >XP

17 nov. 2025, 21:10 UTC

Résultats

XP Inc. 3Q Rev BRL4.67B >XP

17 nov. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov. 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov. 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 nov. 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov. 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17 nov. 2025, 19:16 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 18:20 UTC

Acquisitions, Fusions, Rachats

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov. 2025, 16:45 UTC

Acquisitions, Fusions, Rachats

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov. 2025, 16:16 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 16:15 UTC

Résultats

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov. 2025, 15:40 UTC

Acquisitions, Fusions, Rachats

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov. 2025, 15:22 UTC

Acquisitions, Fusions, Rachats

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov. 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

23.63% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  23.63%

Haut 5 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat